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BACKGROUND: Dendritic cell (DC) vaccination has been shown to induce anti-tumour immune responses in cancer patients, but so far
its clinical efficacy is limited. Recent evidence supports an immunogenic effect of cytotoxic chemotherapy. Pre-clinical data indicate
that the combination of chemotherapy and immunotherapy may result in an enhanced anti-cancer activity. Most studies have focused
on the immunogenic aspect of chemotherapy-induced cell death, but only few studies have investigated the effect of
chemotherapeutic agents on the effector lymphocytes of the immune system.
METHODS: Here we investigated the effect of treatment with oxaliplatin and capecitabine on non-specific and specific DC vaccine-
induced adaptive immune responses. Stage III colon cancer patients receiving standard adjuvant oxaliplatin/capecitabine
chemotherapy were vaccinated at the same time with keyhole limpet haemocyanin (KLH) and carcinoembryonic antigen (CEA)-
peptide pulsed DCs.
RESULTS: In 4 out of 7 patients, functional CEA-specific T-cell responses were found at delayed type hypersensitivity (DTH) skin
testing. In addition, we observed an enhanced non-specific T-cell reactivity upon oxaliplatin administration. KLH-specific T-cell
responses remained unaffected by the chemotherapy, whereas B-cell responses were diminished.
CONCLUSION: The results strongly support further testing of the combined use of specific anti-tumour vaccination with oxaliplatin-
based chemotherapy.
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Until recently, the commonly held opinion was that chemotherapy
and immunotherapy should not be combined because of the
myelosuppressive effect of most cytotoxic agents. However, it has
now become evident that chemotherapeutics can exhibit several
beneficial effects on the immune system (Lake and Robinson,
2005). For example, treatment with gemcitabine results in
increased antigen cross-presentation, T lymphocyte expansion
and T-cell infiltration of tumours (Nowak et al, 2002), and
5-fluorouracil (5-FU) has been described to upregulate tumour
antigen expression on colorectal and breast cancer cells (Correale
et al, 2003). Furthermore, suppressive regulatory T cells are
depleted by several chemotherapeutics also resulting in enhanced
T-cell reactivity (Correale et al, 2005a; Ghiringhelli et al, 2007).
In addition, treatment with non-myeloablative lymphodepleting
chemotherapy results not only in reduced regulatory T-cell
frequencies, but also provides ‘space’ in the bone marrow for
naive T cells to proliferate upon adoptive T-cell transfusion
(Dudley et al, 2002). Using this strategy, significant clinical results
have been obtained in metastatic melanoma patients (Dudley et al,
2005). Pioneering work by Zitvogel and colleagues has shown that
the cytotoxic agents oxaliplatin and doxorubicin induce immuno-
genic cell death, as upon treatment with these agents, tumour cells
transport calreticulin to their cell surface. The exposure of
calreticulin provides a signal that is recognised by dendritic cells
(DCs) and ultimately results in phagocytosis of the tumour cells
(Obeid et al, 2007). Exposure of tumour cells to oxaliplatin results
in the release of high mobility group box 1 (HMGB1) protein, that
activates DCs in a toll-like receptor-4 (TLR4)-dependent manner
(Apetoh et al, 2007). The clinical impact of this immune pathway
in colorectal cancer patients is emphasised by the recent
observation that patients carrying the TLR4 loss-of function allele
Asp299Gly exhibit reduced progression-free and overall survival in
response to oxaliplatin as compared with patients carrying the
normal TLR4 allele (Tesniere et al, 2009).
Previous studies in animal models provide a rationale for the
combination of chemotherapy and immunotherapy in colon
cancer. In a murine model, T-cell responses against the colon
Received 18 June 2010; revised 1 September 2010; accepted 7 September
2010; published online 5 October 2010
*Correspondence: Dr CJA Punt; E-mail: c.punt@onco.umcn.nl
British Journal of Cancer (2010) 103, 1415–1421


























scancer-associated antigen thymidylate synthase that were induced
by a peptide vaccine were not hampered by the administration of
5-FU. The combination of peptide vaccination and 5-FU resulted
in a significant delay in tumour growth as compared with
treatment with peptide or 5-FU alone (Correale et al, 2005b).
Similarly, it was shown in a murine colon cancer model that the
addition of 5-FU/leucovorin or irinotecan to bone marrow-derived
DC vaccination did not diminish the immunogenicity of the
vaccine (Bourquin et al, 2006). Small proof-of-concept clinical
trials in cancer patients indicate that the efficacy of anti-cancer
vaccines may indeed be enhanced by chemotherapy (Kaufman
et al, 2008; Nistico et al, 2008), however additional studies on
scheduling and appropriate combinations are warranted.
Platinum-based chemotherapy represents a cornerstone in the
systemic treatment of many types of cancer (Desoize and
Madoulet, 2002). Besides their direct cytotoxic effects, platinum
anti-cancer drugs may also exert their clinical effect through
indirect activation of the immune system via induction of
immunogenic tumour cell death (Apetoh et al, 2007; Obeid et al,
2007; Tesniere et al, 2009). Most studies however, mainly focused
on the effect of chemotherapy on tumour cells and antigen-
presenting cells. Little attention has been paid to the effect of
chemotherapy on the effector lymphocytes of the immune system.
Although neutropenia is a common side effect of chemotherapy in
the treatment of solid tumours, lymphopenia is rarely observed.
A stimulatory effect of chemotherapy on tumour immunogenicity
without impairing immune effector cell function would provide a
strong rationale to develop novel chemoimmunotherapeutic
strategies. For this reason, we investigated whether an oxaliplatin-
based chemotherapy regimen combined with antigen-specific




This was an open-label, single-institution, single-arm exploratory
study in which patients with stage III colon cancer received
adjuvant treatment with monocyte-derived mature DCs loaded
with carcinoembryonic antigen (CEA)-peptide in combination
with standard oxaliplatin/capecitabine chemotherapy. Approval
from the local regulatory committee was obtained.
Objectives
The primary end point was to assess the immunogenicity of the
vaccine during oaxaliplatin/capecitabine chemotherapy. Secondary
end points were the toxicity and the feasibility of CEA-specific
vaccination in colon cancer patients, during chemotherapy.
Patients
Inclusion criteria included: patients with stage III colon cancer,
HLA-A0201 phenotype, ECOG performance status 0–1, age above
18 years, initiation of adjuvant chemotherapy o8 weeks since
surgery for the primary tumor, no previous chemotherapy,
adequate bone marrow, kidney and hepatic function and written
informed consent. Exclusion criteria included: the use of
immunosuppressive drugs, a history of second malignancy and
other serious concomitant diseases preventing the safe adminis-
tration of study drugs or likely to interfere with the study end
points.
DC preparation
DCs were generated as described previously (de Vries et al, 2005b;
Lesterhuis et al, 2006). Peripheral blood mononuclear cells
(PBMC) were isolated by PureCell (Medicult, Jyllinge, Denmark)
density gradient centrifugation (30min, 41C, 2100r.p.m.), adherent
monocytes were cultured in Cellgro medium enriched with
500Uml
 1 interleukin-4 and 800Uml
 1 granulocyte macrophage
colony stimulating factor ( all CellGenix, Freiburg, Germany). KLH
(10mgml
 1, Calbiochem, San Diego, CA, USA) was added at day 3
of culture and 2 days before harvesting, we added the maturation
cocktail (prostaglandin E2 (Pharmacia & Upjohn, Puurs, Belgium,
10mgml
 1), tumor necrosis factor-a (10ngml
 1), IL-1-b (5gml
 1)
and IL-6 (15ngml
 1, all CellGenix)).
Cells were harvested at day 7 and part of the cells were loaded
with peptide and put in a syringe for immediate vaccination; the
remaining cells were frozen for the second and third vaccination
and the delayed type hypersensitivity (DTH) (de Vries et al, 2002).
Of each batch of patient DCs, a sample was used for quality
control. Release criteria were as previously described (Figdor et al,
2004).
DCs were pulsed with the wild type CEA-peptide CAP-1
(CEA571 579, YLSGANLNL, Clinalfa, Bubendorf, Switzerland)
(Tsang et al, 1995) directly after harvesting or after thawing
(de Vries et al, 2002, 2003).
Treatment schedule
Patients received eight cycles of oral capecitabine 2000mgm
 2 at
days 1–14 and oxaliplatin 130mgm
 2 intravenously at day 1.
Cycles were repeated every 3 weeks. Before the first cycle, patients
underwent a leukapheresis for collection of PBMCs for the DC
culture. At days 4, 10 and 17 of the first cycle of chemotherapy
patients received three vaccinations intradermally (i.d.) and
intravenously (i.v.; 5 106 i.d./10 106 i.v.) with CEA-peptide
loaded dendritic cells (Figure 1). In pre-clinical models it has been
shown that i.v. administered DCs provide a better anti-tumour
response against visceral metastases, whereas non-visceral meta-
stases respond better to i.d. administered DCs (Mullins et al, 2003).
As both lymphogenous and haematogenous spreading occurs in
colorectal cancer, we chose to combine both routes of adminis-
tration. After completion of the vaccinations a DTH skin test was
performed on day 19, followed by biopsies of DTH injection sites
on day 22. Dexamethasone was not administered as anti-emetic
prophylaxis during the first cycle.
Immunologic monitoring
Analysis of peripheral blood immune cell subsets Within the
CD45þ leukocyte population, PBMCs were stained with anti-
bodies against CD14, CD19, CD3, CD8, CD4 and CD56 (for
distinction of monocytes, B cells, T cells, CTLs, T helper
21 28 35 42
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Figure 1 Treatment schedule.
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slymphocytes and NK cells, respectively). After washing, the
samples were analysed by flowcytometry.
Monitoring of non-specific T-cell stimulatory capacity Peripheral
blood mononuclear cells were obtained by density-gradient
centrifugation at days 1, 4, 10, 17 and 22. Cells were plated in
96-well U-bottom plates, 2 10
5 per well, in RPMI/human serum
of 5% and phytohaemagglutinin (PHA) was added (1mgml
 1).
After 24h, supernatant was harvested for cytokine production
analysis. After 3 days, 1mCi per well of 3H-thymidine was added to
the culture for 8h, after which proliferation was stopped by storing
the culture plate at  201C. Incorporation of 3H-thymidine was
measured in a b-counter. The index was calculated as the counts
ratio between PHA-stimulated PBMC and non-stimulated PBMC.
Monitoring of KLH-specific CD4þ T-cell responses CD4þ T-cell
responses against KLH were measured using a 3H-thymidine
incorporation proliferation assay with PBMCs of the patients at
days 1, 4, 10, 17 and 22. The index was calculated as the counts
ratio between KLH-stimulated PBMCs and non-stimulated PBMCs.
Delayed type hypersensitivity reactions Post-treatment DTH
reactions were performed as described previously (de Vries et al,
2005a). Briefly, CEA-peptide alone (100mg in 100ml), DCs pulsed
with CEA-peptide, DCs pulsed with KLH and CEA-peptide
and DCs pulsed with KLH alone (0.4–5 10
5 DCs each in
B100–200ml) were injected i.d., 5–10cm from an inguinal lymph
node at different sites, in the back of the patients. The maximum
diameter of induration was measured after 48h. T-cell culture
from DTH biopsies was performed in low dose IL-2 (Proleukin,
Chiron, the Netherlands 100Uml
 1) for B2 weeks without ex vivo
re-stimulation with antigen as described before (de Vries et al,
2005a).
MHC tetramer staining DTH-derived cells (1 10
5 cells in 10ml)
or PBMCs (1 10
6 cells in 10ml) were incubated with PE-labeled
CEA and cytomegalovirus (CMV) tetrameric–MHC complexes
(Sanquin, Amsterdam, the Netherlands) for 60min at room
temperature. In the last 20min of this incubation, FITC-conjugated
monoclonal antibodies directed against CD8 (Becton Dickinson,
Breda, Netherlands) were added. After washing, the samples were
analysed by flowcytometry. For peripheral blood at least 1 10
6
PBMCs were analysed and for DTH-infiltrating T cells all available
cells were analysed. In all analyses, CEA tetramer staining was
compared with CMV tetramers as a negative control.
Cytokine secretion Production of cytokines by the total popula-
tion of DTH-derived cells was measured in response to T2 cells
pulsed with CEA-peptide or an irrelevant HLA-A2.1 binding
peptide (tyrosinase or G250). Cytokine production was measured
in supernatants after 16h by cytometric bead array (Th1/Th2
Cytokine CBA 1; BD Pharmingen, Breda, Netherlands). IFN-g
production was considered positive when IFN-g-levels of DTH-
infiltrating T cells were more than 10-fold higher after co-
incubation with CEA-loaded T2 cells compared with co-incubation
with T2 cells loaded with irrelevant antigen.
RESULTS
Patients and toxicity
In all, seven patients were included in this study with a median age
of 55 years (range 47–75). All patients had stage III colon cancer.
Most patients experienced grade 1 fever and flu-like symptoms
after vaccination. One patient had a grade 2 allergic reaction of
unknown cause after two vaccinations, consisting of generalised
exanthema with fever and pruritus for which he was treated with
anti-histamines. The third vaccination was without symptoms.
Other toxicities (grade 2 nausea/vomiting, one patient; grade 1
diarrhoea, one patient; grade 3 neurotoxicity, one patient) were
considered to be related to the chemotherapy. With a follow-up of
10–35 months (median 18 months), all patients are recurrence-
free.
Peripheral blood subsets during treatment
Peripheral blood frequencies of mononuclear cells did not
significantly decrease during treatment with oxaliplatin/capecita-
bine (Figure 2, Supplementary Figure 1). The total number of
T cells (CD3þ), T helper cells (CD4þ), cytotoxic T cells (CD8þ),
B cells (CD19þ), monocytes (CD14þ) and natural killer cells
(CD3-/CD56þ) remained stable during chemotherapy.
Non-specific immune reactivity during oxaliplatin/
capecitabine
To test whether treatment with oxaliplatin/capecitabine affects
overall T-cell reactivity that could influence the efficacy of DC
vaccination, we tested the PHA-induced T-cell proliferative
response at different time points during treatment (Figure 3).
Surprisingly, we found a striking increase in the proliferative
capacity of peripheral blood T cells, in most cases directly after
infusion of the oxaliplatin (Figure 3A). In addition, the IFN-g
release upon PHA-stimulation increased (Figure 3B). As this has
not been reported before or after DC vaccination, and as we also
observed this in a control group of patients that were treated
with platinum compounds alone (Supplementary Patients and
methods and Supplementary Figure 2), we conclude that this is a
platinum-effect and not due to the DC vaccine. When peripheral
blood lymphocytes of three healthy donors were stimulated
with PHA after 24h of in vitro culture with oxaliplatin, we did
not observe an enhanced effect of the platinum treatment
(Supplementary Figure 3).
KLH-specific immune responses during oxaliplatin/
capecitabine
To test whether de novo antigen-specific T- and B-cell immune
responses can be induced during treatment with oxaliplatin and
capecitabine, we loaded the DCs with the control antigen KLH and
measured the proliferative T-cell response and antibody response
(Figure 4, Table 1). We observed a robust CD4þ proliferative
response against KLH in all patients, comparable to previous
studies in colorectal cancer and melanoma patients who were
vaccinated with the same vaccine without chemotherapy
(Figure 4A) (de Vries et al, 2003, 2005a; Lesterhuis et al, 2006).
However, in all but two patients antibody responses against KLH
were absent (Figure 3B). In the patients with an antibody response,
this response was only weak. This is in contrast to our previous
studies in which we could detect a response in almost all
vaccinated patients (de Vries et al, 2003).
Vaccine-induced CEA-specific immune responses during
oxaliplatin/capecitabine
We next determined the vaccine-induced tumor antigen-specific
immune response in DTH biopsies as previously published
(de Vries et al, 2005a; De Vries et al, 2007). In four out of seven
patients, we found CEA-specific T cells by means of tetramer
analysis (Figure 5A, Table 1). In a previous cohort of colorectal
cancer patients that were treated with the same vaccine without
chemotherapy, we found CEA-specific DTH-infiltrating T cells in
5 out of 11 patients after one vaccination cycle (Lesterhuis et al,
2006). Thus, the efficacy of the vaccine does not seem to be
negatively influenced by chemotherapy in terms of the induction
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Figure 3 (A) Proliferative non-specific T-cell response upon PHA-stimulation during treatment with oxaliplatin/capecitabine and DC vaccination. In all
patients, an increase in proliferation was observed during treatment. (B) Also the IFN-g production upon PHA-stimulation increased during treatment (data
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Figure 4 All patients showed a proliferative CD4þ T-cell response against the control antigen KLH. (A) A representative patient (patient 7) is shown.
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Figure 2 Frequencies of PBMC subsets during treatment with oxaliplatin/capecitabine and DC vaccination. Means with s.d. are depicted. (A) Total T cells
(CD3þ). (B) T helper cells (CD4þ). (C) Cytotoxic T cells (CD8þ). (D) Natural killer cells (CD3-/CD56þ). (E) Monocytes (CD14þ). (F) B cells
(CD19þ).
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sof tumor antigen-specific immunity. Furthermore, the function-
ality of the T cells remained unaffected as they produced high
amounts of IFN-g and IL-2 upon co-culture with CEA-loaded
target cells (Figure 5B).
DISCUSSION
Despite ample evidence for chemotherapy-induced immunogenic
cell death, much less is known about the effect of chemotherapy on
the effector lymphocytes of the immune system in vivo in cancer
patients. Therefore, we conducted a clinical pilot trial to test the
immunogenicity of a DC vaccine in stage III colon cancer patients
treated with standard adjuvant oxaliplatin and capecitabine
chemotherapy. We found that robust de novo KLH-specific T-cell
responses could very well be induced during the chemo-
therapy regime. However, B-cell responses were hampered when
compared with previous studies using the same vaccine without
chemotherapy (de Vries et al, 2003, 2005a). No additional toxicity
was observed, apart from the side effects that frequently occur for
both treatment strategies separately.
In four out of seven patients, we observed a functional CEA-
specific T-cell response upon vaccination with CEA-loaded DCs.
Although the number of patients is limited, this is comparable to a
previous cohort of colorectal cancer patients that were treated with
the same vaccine without chemotherapy (Lesterhuis et al, 2006).
To date, none of the treated patients have had a relapse. However,
given the adjuvant nature of the treatment, the short follow-up and
the limited numbers of patients, no conclusion can be drawn on
the clinical efficacy of adding DC vaccination to standard adjuvant
chemotherapy. Other studies investigating the combination of
immunotherapy and chemotherapy have been performed in
colorectal cancer patients. Kaufman and colleagues vaccinated
metastatic colorectal cancer patients with a CEA-ALVAC vaccine
in combination with irinotecan, 5-FU and leucovorin and found
that the CEA-specific T-cell response was unaffected by the
chemotherapy (Kaufman et al, 2008). Similar observations were
made, using the same chemotherapeutics but different vaccines
(Weihrauch et al, 2005; Harrop et al, 2008).
Surprisingly, the non-specific T-cell proliferative capacity
increased upon chemotherapy treatment in most patients shortly
after infusion of the oxaliplatin. Previously, others had found a
similar effect for gemcitabine in a murine model (Nowak et al,
2002), but for platinum-based compounds this has not been
reported before. Although oxaliplatin has been described to induce
an immunogenic type of cancer cell death, which could result in
DC activation and subsequent non-specific T-cell activation
(Apetoh et al, 2007; Ghiringhelli et al, 2009), we consider this
mechanism less likely in our study as the patients were treated in
an adjuvant setting, that is in the absence of macroscopic tumor.
A possible explanation for the increased T-cell activation may lie
in our recent finding that platinum compounds dephosphorylate
signal transducer and activator of transcription 6 (STAT6)
(Lesterhuis et al, 2010). This protein is of crucial importance for
the induction of T helper 2 immunity and hence for the
development of B-cell responses. Inactivation of STAT6 may result
in enhanced T helper 1 responsiveness and at the same time in
decreased B-cell activation, as observed in this study. The fact that
we did not find this effect when lymphocytes of healthy donors
were stimulated with PHA after 24h of culture in the presence of
oxaliplatin, suggests that this mechanism mainly works through
antigen-presenting cells and not lymphocytes. However, it is
questionable whether the in vitro conditions properly mimic the
in vivo situation. More research is needed to decipher the exact
effects of platinum compounds on immune cells.
Our study is the first to investigate the combined use of specific
vaccination with oxaliplatin-based chemotherapy. Oxaliplatin
appears to be a promising drug to include in chemoimmunother-
apeutic regimens, as it induces an immunogenic type of tumor cell
death resulting in enhanced DC activation (Apetoh et al, 2007;
Ghiringhelli et al, 2009; Tesniere et al, 2009). Our findings that the
immune effector cells remain unaffected and that T-cell prolif-
erative capacity following PHA stimulation even increases upon
oxaliplatin treatment further support this strategy.
Although DC vaccinations frequently induce immune responses,
objective clinical remissions are rare (Lesterhuis et al, 2008). One
possible explanation is that DC vaccination may be more effective
in residual microscopic disease, as it lacks a direct cytotoxic effect
that is likely required in a macroscopic disease. On the other hand,
cytotoxic chemotherapy also does not result in complete tumour
eradication in the majority of patients with metastatic solid
tumours. Therefore, the combination of DC vaccination with
cytotoxic chemotherapy is an attractive strategy. Our data
demonstrate the feasibility of the combination of these two
strategies and provide the rationale for future studies that
investigate the clinical efficacy of this strategy.
Table 1 Antigen-specific immune responses
Patient 1 2 3 4 5 6 7
KLH CD4+ response + + +++++
KLH antibody response     ++ 
CEA-tetramers peripheral blood        
CEA-tetramers DTH   +n t   +
CEA-specific IFN-g response in DTH + + +    +
Abbreviations: CEA¼carcinoembryonic antigen; DTH¼delayed type hypersensitivity;
IFN¼interferon; KLH¼keyhole limpet haemocyanin; nt¼not tested. Summary of all






















Figure 5 In four out of seven patients, CEA-specific DTH-infiltrating T cells were observed after completion of vaccination, either by (A) tetramer staining
or (B) IFN-g and IL-2 release upon co-culture with CEA-loaded target cells. Data from a representative patient (no. 2) are shown.
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